Cell and gene therapies (CGTs) promise transformative outcomes for patients - but too often, that promise stalls at launch or fizzles in-market as teams face low patient volumes, complex site onboarding, and commercialization models not built for high-touch, low-scale therapies.

In this panel discussion, CGT leaders from Novartis, Orca Bio, BioMarin and Beghou share firsthand lessons from some of the field’s most notable launches.

You’ll hear what actually worked when the rubber met the road - not just in theory, but in the real-world complexity of people, process, data, and technology.

Key topics covered:

• What’s working and not working: Why do some CGTs succeed while others stall? What are key lessons learned and "watch outs" leading into a CGT launch?
• Clinical to commercial:  How and when do you engage with other functions - especially commercial - during development? Which functions are most critical to successful launches, and how does cross-functional collaboration evolve from development to launch?
• Tailoring the model: In CGT, strategies around partnerships, access, cost, and supply chain vary based on factors like cell vs. gene, rare vs. broad indications, and single-asset vs. portfolio. What are one or two areas you see as most critical to adapt?
• Operationalizing for complexity: Do you think that the data, tech, and workflows are evolving at the pace science is moving to meet the unique demands of CGT launches?
• Future Outlook: How do we overcome CGT challenges? What innovations will we need to bring about to reduce complexity and achieve more success?

Whether you’re preparing for your first CGT launch or looking to course-correct an in-market product, this session delivers grounded insights and practical strategies to make commercialization work.